Analysis of Opicapone’s official launch time and clinical promotion status

Opicapone (Opicapone) is an oral peripheral selective COMT inhibitor, mainly used to treat the "on-- off" phenomenon associated with Parkinson's disease. The drug was first developed by the Finnish pharmaceutical company NeuroSearch and Japan's Mitsubishi Tanabe Pharma (Mitsubishi Tanabe Pharma). Multiple clinical trials have verified that it has significant advantages in prolonging the efficacy of levodopa and improving motor fluctuations.

Opicapone was first approved for marketing in Europe. The European Medicines Agency (EMA) officially approved Opicapone tablets in 2016 for the adjuvant treatment of patients with Parkinson's disease accompanied by motor fluctuations. Subsequently, the Japan Pharmaceuticals and Medical Devices Agency (PMDA) also approved the drug for marketing in the Japanese market, marking the gradual entry of Opicapone into clinical application on an international scale. The U.S. Food and Drug Administration (FDA) approved its use in the U.S. market in 2019, further broadening its global market layout.

In terms of clinical promotion, opicapone can significantly prolong the "on" state time of patients and reduce the frequency of "off" state through combined use with levodopa. Multiple clinical trials and real-world studies have shown that the drug is well tolerated and its adverse reactions are relatively controllable, mainly including mild to moderate constipation and decreased blood pressure. These findings motivate physicians to consider opicapone as an effective adjunct to levodopa therapy in the management of Parkinson's disease.

Domestic clinical promotion is also gradually carried out. With the improvement of imported drug registration and medical insurance policies, some regional hospitals have begun clinical use of Opicapone, especially for patients with mid-to-late Parkinson's disease who have difficulty controlling movement fluctuations. At the same time, pharmaceutical companies improve doctors' awareness of the drug's efficacy and safety through academic promotion, clinical training and patient education, and gradually promote its standardized application and popularization in the country.

Reference link:https://www.drugs.com